EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
31 mayo 2020
Presenting a 👉Pooled Safety Analysis of Single-Agent #Lurbinectedin VS Topotecan (Results From a Randomized Phase III Trial CORAIL & A Phase II Basket Trial). Started This Study For Ewing #Sarcoma👉& Found That Lurbinectedin Is Active In #Small Cell #Lung Cancer .